70 research outputs found
Counter lung
Counter lung, incorporated in closed-loop rebreathing system, accommodates user's breathing tidal volume so that the loop pressure is relatively constant during breathing cycles
Aircrew oxygen system development Flight test report
Flight tests of breadboard version of aircrew oxygen syste
Aircrew oxygen system
Closed-loop rebreather system which includes pilot provides oxygen for use in aircraft by safe, reliable method of low weight and size and reduces expense of ground equipment. Water electrolysis generated oxygen is fed into rebreather loop which allows nitrogen elimination and water and carbon dioxide removal
On-board aircraft oxygen generating system
Onboard oxygen generation equipment with minimal ground support equipment and applicable to spacecraft and submarine us
Aircrew oxygen system development carbon dioxide concentrator subsystem report
Carbon dioxide concentrator subsystem for closed loop aircrew oxygen syste
Aircrew oxygen system development man-in-the-loop test report
Manned testing of flight breadboard oxygen syste
Carbon dioxide concentration system Interim report no. 1
Electrochemical carbon dioxide concentration system for purifying space cabin atmospher
The calcilytic agent NPS 2143 rectifies hypocalcemia in a mouse model with an activating calcium-sensing-receptor (CaSR) mutation:relevance to autosomal dominant hypocalcemia type 1 (ADH1)
Autosomal dominant hypocalcemia type 1 (ADH1) is caused by germline gain-of-function mutations of the calcium-sensing receptor (CaSR) and may lead to symptomatic hypocalcemia, inappropriately low serum parathyroid hormone (PTH) concentrations and hypercalciuria. Negative allosteric CaSR modulators, known as calcilytics, have been shown to normalise the gain-of-function associated with ADH-causing CaSR mutations in vitro and represent a potential targeted therapy for ADH1. However, the effectiveness of calcilytic drugs for the treatment of ADH1-associated hypocalcemia remains to be established. We have investigated NPS 2143, a calcilytic compound, for the treatment of ADH1 by in vitro and in vivo studies involving a mouse model, known as Nuf, which harbors a gain-of-function CaSR mutation, Leu723Gln. Wild-type (Leu723) and Nuf mutant (Gln723) CaSRs were expressed in HEK293 cells and the effect of NPS 2143 on their intracellular calcium responses determined by flow cytometry. NPS 2143 was also administered as a single intraperitoneal bolus to wild-type and Nuf mice and plasma concentrations of calcium and PTH, and urinary calcium excretion measured. In vitro administration of NPS 2143 decreased the intracellular calcium responses of HEK293 cells expressing the mutant Gln723 CaSR in a dose-dependent manner, thereby rectifying the gain-of-function associated with the Nuf mouse CaSR mutation. Intraperitoneal injection of NPS 2143 in Nuf mice led to significant increases in plasma calcium and PTH without elevating urinary calcium excretion. These studies of a mouse model with an activating CaSR mutation demonstrate NPS 2143 to normalize the gain-of-function causing ADH1, and improve the hypocalcemia associated with this disorder
Gα11 mutation in mice causes hypocalcemia rectifiable by calcilytic therapy
Heterozygous germline gain-of-function mutations of G-protein subunit α11 (Gα11), a signaling
partner for the calcium-sensing receptor (CaSR), result in autosomal dominant hypocalcemia
type 2 (ADH2). ADH2 may cause symptomatic hypocalcemia with low circulating parathyroid
hormone (PTH) concentrations. Effective therapies for ADH2 are currently not available and a
mouse model for ADH2 would help in assessment of potential therapies. We hypothesised that a
previously reported dark skin mouse mutant (Dsk7), which has a germline hypermorphic Gα11
mutation, Ile62Val, may be a model for ADH2 and allow evaluation of calcilytics, which are
CaSR negative allosteric modulators, as a targeted therapy for this disorder. Mutant Dsk7/+
and Dsk7/Dsk7 mice were shown to have hypocalcemia and reduced plasma PTH
concentrations, similar to ADH2 patients. In vitro studies showed the mutant Val62 Gα11 to upregulate
CaSR-mediated intracellular calcium and MAPK signaling, consistent with a gain-offunction.
Treatment with NPS-2143, a calcilytic compound, normalised these signaling
responses. In vivo, NPS-2143 induced a rapid and marked rise in plasma PTH and calcium
concentrations in Dsk7/Dsk7 and Dsk7/+ mice, which became normocalcemic. Thus, these
studies have established Dsk7 mice, which harbor a germline gain-of-function Gα11 mutation, as
a model for ADH2; and demonstrated calcilytics as a potential targeted therapy
Mutant Mice With Calcium-Sensing Receptor Activation Have Hyperglycemia That Is Rectified by Calcilytic Therapy
The calcium-sensing receptor (CaSR) is a family C G-protein-coupled receptor (GPCR) that plays a pivotal role in extracellular calcium homeostasis. The CaSR is also highly expressed in pancreatic islet α- and β-cells that secrete glucagon and insulin, respectively. To determine whether the CaSR may influence systemic glucose homeostasis, we characterized a mouse model with a germline gain-of-function CaSR mutation, Leu723Gln, referred to as Nuclear flecks (Nuf). Heterozygous- (CasrNuf/+) and homozygous-affected (CasrNuf/Nuf) mice were shown to have hypocalcemia in association with impaired glucose tolerance and insulin secretion. Oral administration of a CaSR antagonist compound, known as a calcilytic, rectified the glucose intolerance and hypoinsulinemia of CasrNuf/+ mice, and ameliorated glucose intolerance in CasrNuf/Nuf mice. Ex vivo studies showed CasrNuf/+ and CasrNuf/Nuf mice to have reduced pancreatic islet mass and β-cell proliferation. Electrophysiological analysis of isolated CasrNuf/Nuf islets showed CaSR activation to increase the basal electrical activity of β-cells independently of effects on the activity of the ATP-sensitive K+ (KATP) channel. CasrNuf/Nuf mice also had impaired glucose-mediated suppression of glucagon secretion, which was associated with increased numbers of α-cells and a higher α-cell proliferation rate. Moreover, CasrNuf/Nuf islet electrophysiology demonstrated an impairment of α-cell membrane depolarization in association with attenuated α-cell basal KATP channel activity. These studies indicate that the CaSR activation impairs glucose tolerance by a combination of α- and β-cell defects and also influences pancreatic islet mass. Moreover, our findings highlight a potential application of targeted CaSR compounds for modulating glucose metabolism
- …